Investment Research & Advisory Group Inc. Raises Position in Danaher Co. (NYSE:DHR)

Investment Research & Advisory Group Inc. increased its holdings in shares of Danaher Co. (NYSE:DHR) by 3.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 5,338 shares of the conglomerate’s stock after purchasing an additional 177 shares during the period. Investment Research & Advisory Group Inc.’s holdings in Danaher were worth $1,225,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Coronation Fund Managers Ltd. raised its stake in Danaher by 29.9% in the 2nd quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock worth $1,596,000 after acquiring an additional 1,470 shares during the last quarter. Peloton Wealth Strategists lifted its holdings in shares of Danaher by 1.3% during the second quarter. Peloton Wealth Strategists now owns 5,764 shares of the conglomerate’s stock worth $1,440,000 after purchasing an additional 75 shares during the period. Oliver Lagore Vanvalin Investment Group boosted its position in Danaher by 12.3% in the second quarter. Oliver Lagore Vanvalin Investment Group now owns 4,098 shares of the conglomerate’s stock valued at $1,024,000 after buying an additional 448 shares during the last quarter. Goodman Advisory Group LLC acquired a new position in Danaher in the 2nd quarter worth approximately $209,000. Finally, Texas Capital Bank Wealth Management Services Inc raised its position in Danaher by 2.0% during the 2nd quarter. Texas Capital Bank Wealth Management Services Inc now owns 32,138 shares of the conglomerate’s stock worth $8,030,000 after buying an additional 628 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Guggenheim initiated coverage on shares of Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective on the stock. Raymond James decreased their price objective on Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a report on Tuesday, January 21st. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, Scotiabank initiated coverage on shares of Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Trading Up 0.1 %

Shares of DHR opened at $245.95 on Friday. The firm’s fifty day moving average is $235.33 and its two-hundred day moving average is $253.45. The stock has a market cap of $177.65 billion, a PE ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 52-week low of $225.42 and a 52-week high of $281.70.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.